Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

Running, not enrolling

Conditions studied: Type 2 Diabetes, Heart Failure

In brief

This cohort study aims to assess the comparative effectiveness of tirzepatide versus semaglutide with respect to cardiovascular events in patients with type 2 diabetes and heart failure with preserved ejection fraction.

Key facts

Study ID

NCT06980623

Run by

Brigham and Women's Hospital

People needed

26000

Starts

2025-01-01

Expected to finish

2026-10-01

Last updated by the study team

2026-05-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who are new users of tirzepatide or new users of semaglutide
• Patients with diagnosis of T2D and HFpEF, i.e., EF >= 45%.
• Age >= 18 years old
• Patients with continuous health plan enrollment before and including the treatment initiation date

You may not qualify if…

• Patients with missing age or sex information
• Patients with type 1 diabetes mellitus, secondary or gestational diabetes
• History of diabetes related complications
• Patients with related chronic diseases.
• History of gastrointestinal conditions.
• Previous exposure to other GLP-1RA and pramlintide
• Patients with prescription dispensing for both tirzepatide and semaglutide on cohort entry date

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.